AU2019360216A1 - Immunomodulating polynucleotide conjugates and methods of use - Google Patents
Immunomodulating polynucleotide conjugates and methods of use Download PDFInfo
- Publication number
- AU2019360216A1 AU2019360216A1 AU2019360216A AU2019360216A AU2019360216A1 AU 2019360216 A1 AU2019360216 A1 AU 2019360216A1 AU 2019360216 A AU2019360216 A AU 2019360216A AU 2019360216 A AU2019360216 A AU 2019360216A AU 2019360216 A1 AU2019360216 A1 AU 2019360216A1
- Authority
- AU
- Australia
- Prior art keywords
- conjugate
- seq
- group
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747070P | 2018-10-17 | 2018-10-17 | |
| US62/747,070 | 2018-10-17 | ||
| US201862747611P | 2018-10-18 | 2018-10-18 | |
| US62/747,611 | 2018-10-18 | ||
| PCT/US2019/056619 WO2020081744A1 (en) | 2018-10-17 | 2019-10-16 | Immunomodulating polynucleotide conjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019360216A1 true AU2019360216A1 (en) | 2021-05-13 |
Family
ID=70284225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019360216A Pending AU2019360216A1 (en) | 2018-10-17 | 2019-10-16 | Immunomodulating polynucleotide conjugates and methods of use |
Country Status (12)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025157804A1 (en) * | 2024-01-24 | 2025-07-31 | F. Hoffmann-La Roche Ag | Linkers for site-specific protein conjugation |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| MX2024002187A (es) * | 2021-08-20 | 2024-03-12 | Tallac Therapeutics Inc | Anticuerpos y conjugados de nectina-4. |
| TW202328185A (zh) * | 2021-08-25 | 2023-07-16 | 美商泰勒克療法公司 | SIRP-α抗體及結合物 |
| WO2023081934A1 (en) * | 2021-11-08 | 2023-05-11 | The University Of Chicago | Methods and compositions for pkc-delta inhibition and cancer immunotherapy |
| KR20250039518A (ko) * | 2022-05-18 | 2025-03-20 | 탈락 테라퓨틱스, 인크. | 항-cd22 항체 올리고뉴클레오타이드 접합체를 사용하여 암을 치료하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106061981A (zh) * | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| CN107109405A (zh) * | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| US20180134802A1 (en) * | 2016-01-08 | 2018-05-17 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same |
| JP2019513692A (ja) * | 2016-02-19 | 2019-05-30 | ジェニスフィア・エルエルシー | 核酸キャリア及び治療上の使用方法 |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
-
2019
- 2019-10-16 AU AU2019360216A patent/AU2019360216A1/en active Pending
- 2019-10-16 CA CA3116880A patent/CA3116880A1/en active Pending
- 2019-10-16 MX MX2021004365A patent/MX2021004365A/es unknown
- 2019-10-16 WO PCT/US2019/056619 patent/WO2020081744A1/en not_active Ceased
- 2019-10-16 CN CN201980082021.3A patent/CN113660955A/zh active Pending
- 2019-10-16 IL IL282282A patent/IL282282B2/en unknown
- 2019-10-16 SG SG11202103805SA patent/SG11202103805SA/en unknown
- 2019-10-16 US US17/283,919 patent/US20220096649A1/en not_active Abandoned
- 2019-10-16 EP EP19874575.4A patent/EP3866858A4/en active Pending
- 2019-10-16 KR KR1020217014643A patent/KR20210102204A/ko not_active Ceased
- 2019-10-16 BR BR112021007294-2A patent/BR112021007294A2/pt unknown
- 2019-10-16 JP JP2021546200A patent/JP7536025B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025157804A1 (en) * | 2024-01-24 | 2025-07-31 | F. Hoffmann-La Roche Ag | Linkers for site-specific protein conjugation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7536025B2 (ja) | 2024-08-19 |
| IL282282B1 (en) | 2025-03-01 |
| BR112021007294A2 (pt) | 2021-07-27 |
| IL282282A (en) | 2021-05-31 |
| JP2022508825A (ja) | 2022-01-19 |
| EP3866858A4 (en) | 2022-10-26 |
| US20220096649A1 (en) | 2022-03-31 |
| CN113660955A (zh) | 2021-11-16 |
| SG11202103805SA (en) | 2021-05-28 |
| IL282282B2 (en) | 2025-07-01 |
| MX2021004365A (es) | 2021-07-06 |
| CA3116880A1 (en) | 2020-04-23 |
| WO2020081744A1 (en) | 2020-04-23 |
| KR20210102204A (ko) | 2021-08-19 |
| EP3866858A1 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7536025B2 (ja) | 免疫調節性ポリヌクレオチドコンジュゲートと使用方法 | |
| US12527838B2 (en) | Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel | |
| TWI913247B (zh) | 轉穀胺醯胺酶介導之結合 | |
| US11466158B2 (en) | Phthalocyanine dye compounds, conjugates and methods of use thereof | |
| US12378313B2 (en) | Bispecific binding agents binding to CLDN18.2 and CD3 | |
| CN108350082A (zh) | Pd-l1抗体及其用途 | |
| TW202003581A (zh) | 對cd3具特異性之抗體及其用途 | |
| US12098214B2 (en) | Combination therapies for treating cancer | |
| TW202003044A (zh) | 可釋放之抗體結合物 | |
| CA3195303A1 (en) | Glycoconjugates | |
| FI131754B1 (en) | Antibody-exatecan conjugates | |
| EP4543893A1 (en) | N-substituted indole derivatives and conjugates for the treatment of cancer |